We provide you with 20 years of free, institutional-grade data for ICVX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ICVX. Explore the full financial landscape of ICVX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2023-11-14 | 1786255 | ICVX | 10-Q | Url |
| 2023-08-14 | 1786255 | ICVX | 10-Q | Url |
| 2023-05-10 | 1786255 | ICVX | 10-Q | Url |
| 2023-03-30 | 1786255 | ICVX | 10-K | Url |
| 2022-11-14 | 1786255 | ICVX | 10-Q | Url |
| 2022-08-15 | 1786255 | ICVX | 10-Q | Url |
| 2022-05-16 | 1786255 | ICVX | 10-Q | Url |
| 2022-03-30 | 1786255 | ICVX | 10-K | Url |
| 2021-11-15 | 1786255 | ICVX | 10-Q | Url |
| 2021-09-13 | 1786255 | ICVX | 10-Q | Url |
| 2021-07-07 | 1786255 | ICVX | S-1 | Url |
Icosavax(NASDAQ:ICVX) 
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial ...
Website: https://icosavax.com/
Founded: 2017
CEO: Adam Simpson
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ICVX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.